Arrestage International 10-K 8 Sep 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Arrestage International, Inc.
Entity Central Index Key	0001666267
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Number	000-55010
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	AZ
Entity Common Stock, Shares Outstanding	3,600,000
Entity Public Float		$ 208,000
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	Yes

Balance Sheet

Balance Sheet - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets
Cash In Bank	$ 1,699	$ 3,660
Prepaid Expenses	87	3,246
Total Current Assets	1,786	6,906
Other Assets
Trademark License'	50,000	50,000
Impairment-Trademark License	(50,000)	(50,000)
Prepaid Expenses
Total Other Assets
TOTAL ASSETS	1,786	6,906
Current Liabilities
Accounts Payable	3,038	8,303
Notes Payable-Related Party	219,879	150,857
Accrued Interest Payable	31,960	16,046
License Fee Payable	25,790	25,790
Total Current Liabilities	280,667	200,996
Total Liabilities	280,667	200,996
Stockholders' (Deficit)
Preferred Stock, $0.001 par value, 5,000,000 shares of preferred shares authorized, no shares of preferred stock outstanding.
Common Stock, $0.001 par value, 30,000,000 shares authorized, 3,600,000 shares issued and outstanding as of December 31, 2019 and December 31, 2018	3,600	3,600
Additional Paid-in Capital	148,851	148,851
Accumulated Deficit	(431,332)	(346,541)
Total Stockholders' (Deficit)	(278,881)	(194,090)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 1,786	$ 6,906

Balance Sheet (Parenthetical)

Balance Sheet (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	3,600,000	3,600,000
Common stock, shares outstanding	3,600,000	3,600,000

Statement of Operations

Statement of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenues
Operating Expenses
Bank Charges	96	87
Professional and Legal Fees	42,611	82,228
Accounting and Bookkeeping Fees	25,849	23,290
Other Expenses	820	2,660
Total Operating Expenses	69,376	108,265
Other Expenses
Interest Expense	15,914	9,430
Total Expenses	85,290	117,695
Net Operating Income (Loss)	(85,290)	(117,695)
Other Income
Gain on Forgiveness of Debt	500
Total Other Income	500
Net Income (Loss)	$ (84,790)	$ (117,695)
Per Share	$ (0.02)	$ (0.03)
Weighted Average number of shares outstanding	3,600,000	3,600,000

Statement of Changes in Stockho

Statement of Changes in Stockholders (Deficit) - USD ($)	Common Stock	Additional Paid In Capital	Retained Earnings (Acc Deficit)	Total
Balance at Dec. 31, 2015	$ 3,561	$ 110,140	$ (155,037)	$ (41,336)
Balance, shares at Dec. 31, 2015	3,561,250
Issuance of Stock for cash, net of offering costs	$ 39	38,711		38,750
Issuance of Stock for cash, net of offering costs, shares	38,750
Net Income (Loss)			(30,794)	(30,794)
Balance at Dec. 31, 2016	$ 3,600	148,851	(185,831)	(33,380)
Balance, shares at Dec. 31, 2016	3,600,000
Net Income (Loss)			(43,016)	(43,016)
Balance at Dec. 31, 2017	$ 3,600	148,851	(228,847)	(76,396)
Balance, shares at Dec. 31, 2017	3,600,000
Net Income (Loss)			(117,694)	(117,694)
Balance at Dec. 31, 2018	$ 3,600	148,851	(346,541)	(194,090)
Balance, shares at Dec. 31, 2018	3,600,000
Net Income (Loss)			(84,790)	(84,790)
Balance at Dec. 31, 2019	$ 3,600	$ 148,851	$ (431,331)	$ (278,881)
Balance, shares at Dec. 31, 2019	3,600,000

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash Flows from operating activities:
Net (Loss)	$ (84,790)	$ (117,695)
Adjustments to reconcile net (loss) to net cash used in operating activities:
(Increase) Decrease in Prepaid Expenses	3,159	12,005
Increase (Decrease) in Accounts Payable	(5,265)	8,302
Increase in accrued interest payable	15,914	9,430
Total Adjustments	13,808	29,737
Net Cash (used in) Operating Activities	(70,983)	(87,957)
Cash Flows from financing activities:
Proceeds from (payments on) note payable-related party	69,022	88,705
Proceeds from sale of common stock
Net cash provided by financing activities	69,022	88,705
Net increase (decrease) in cash	(1,961)	748
Cash Balance at Beginning of Period	3,660	2,911
Cash Balance at End of Period	1,699	3,660
Interest Paid	0	0
Income taxes paid	$ 0	$ 0

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES This summary of significant accounting policies of Arrestage International, Inc. (the "Company") is presented to assist in understanding the Company's financial statements. The financial statements and footnotes are representations of the Company's management, who is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles in the United States of America and have been consistently applied in the preparation of the financial statements. Organization and Description of the Business The Company was incorporated under the laws of the State of Nevada on June 15, 2011 and is in the Nutraceutical business and holds formulas on skin care products as well as brand formulas, and other intellectual property. Use of Estimates by Management The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents includes cash in banks and highly liquid investments with original maturities of three months or less that are readily convertible into cash and are not subject to significant risk from fluctuations in interest rates. As a result, the carrying amount of cash and cash equivalents approximates fair value. Concentrations of Credit Risk The Company places its cash and cash equivalents with major financial institutions. At December 31, 2019 and December 31, 2018 the Company did not have any cash balances on deposit with banks which exceeded the balance insured by the FDIC, and does not believe that it is subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. Intangible Assets Goodwill and Intangible Assets—Intangible assets with finite useful lives are amortized while intangible assets with indefinite useful lives are not amortized. Amortizable intangible assets are reviewed for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Indefinite-lived intangible assets are tested annually for impairment and when events or changes in circumstances indicate the carrying value may not be recoverable. The appropriateness of the indefinite-life classification of non-amortizable intangible assets is also reviewed as part of the annual testing or when circumstances warrant a change to a finite life. The Company performs its annual impairment testing as of December 31 each year, which is the last day of the Company's fiscal year. Intangible assets with indefinite useful lives (The Trademark License) are tested for impairment at the individual asset level by comparing the fair value of the indefinite-lived intangible asset to its carrying amount. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment charge is recognized to reduce the carrying amount to fair value. Fair values of indefinite-lived intangible assets are estimated using discounted cash flow ("DCF") models. In using a DCF method of establishing a fair value, management must make certain assumptions as to the likelihood of having cash flow from operations in the future based on past performance and prospects of sales in the future. The Company has no history of sales and no orders pending. Therefore, it is not possible to determine an appropriate level of cash receipts from operations into the future. Based on this assumption, during 2014 management determined that the fair value of the Trademark License under Generally Accepted Accounting Principles was zero. Accordingly, the Company has chosen to write the carrying value of the Trademark license to zero as of December 31, 2014. Fair Value of Financial Instruments. Recent Accounting Pronouncements The Company does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements. Ricks and Uncertainties The Company is subject to substantial business risks and uncertainties inherent in starting a new business. There is no assurance that the Company will be able to complete a business combination. Basis of Presentation-Going Concern The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern. However, as reflected in the accompanying financial statements, the Company has no operations, a net loss of ($84,790) for the year ended December 31, 2019, and ($117,695) for the year ended December 31, 2018, an accumulated deficit of ($431,331) as of December 31, 2019 and ($346,542) as of December 31, 2018, and a working capital deficiency of ($278,880) and ($194,090) at December 31, 2019 and December 31, 2018 respectively. This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company's ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. These financial statements are prepared on a going concern basis because the Directors, officers and significant shareholders have undertaken to provide continuing financial support so that the Company is able to pay its debts as and when they fall due. In addition, Management's plans to ensure the Company continues as a going concern include the pay-down of outstanding debt of the Company and funding of future operations using proceeds from the revenues expected to be generated from the sale of products and services within acquired companies. While the Company looks to acquire targeted acquisitions, adverse changes in market conditions or limits on the Company's ability to obtain financing could limit the Company's acquisition of such targets and the production, marketing and sale of products and services of the targeted acquisitions. The impact of such eventualities could influence future operations of the Company. Income Taxes The Company records deferred taxes in accordance with Statement of Financial Accounting Standards (SFAS) ASC 740, "Accounting for Income Taxes." The statement requires recognition of deferred tax assets and liabilities for temporary differences between the tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, the effect of net operating losses, based upon the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Earnings per Share Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding. There were no options or warrants outstanding at December 31, 2019 nor December 31, 2018. Diluted earnings per share is not shown for the periods in which the Company incurs a loss because it would be anti-dilutive. Other The Company has selected December 31 as its fiscal year end. The Company has paid no dividends. No advertising expense has been incurred. The Company consists of one reportable business segment. The Company has not entered into any leases.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 2 - INCOME TAXES Deferred income taxes arise from temporary timing differences in the recognition of income and expenses for financial reporting and tax purposes. The Company's deferred tax assets consist entirely of the benefit from net operating loss (NOL) carry forwards. The net operating loss carry forward if not used, will expire in various years through 2037, and is severely restricted as per the Internal Revenue code if there is a change in ownership. The Company's deferred tax assets are offset by a valuation allowance due to the uncertainty of the realization of the net operating loss carry forwards. Net operating loss carry forwards may be further limited by other provisions of the tax laws. With few exceptions, our income tax returns are no longer subject to Federal tax examinations by tax authorities for years before December 31, 2012. The Company is subject to federal and state income tax. No provision for tax has been made at December 31, 2019, and 2018 as the Company had no taxable income for both periods. The following table reconciles the Company's statutory tax rate to its effective tax rate as a percentage of income before income taxes: 2019 2018 U.S. statutory rate 21 % 34 % Valuation allowance -21 % -34 % Effective tax rate 0 % 0 % The components of the Company's deferred income tax assets are set forth below: Year Ending Estimated NOL Carry-forward NOL Expires Estimated Tax Benefit from NOL Valuation Allowance Change in Valuation Allowance Net Tax Benefit December 31, 2019 $ 315,375 Various $ 66,229 $ 66,229 $ 13,826 $ 0 December 31, 2018 $ 249,537 Various $ 52,403 $ 52,403 $ 17,868 $ 0 December 31, 2017 $ 164,450 Various $ 34,535 $ 34,535 $ 7,414 $ 0 December 31, 2016 $ 129,147 Various $ 27,121 $ 27,121 $ 8,306 $ 0 December 31, 2015 $ 89,595 Various $ 18,815 $ 18,815 $ 631 $ 0 December 31, 2014 $ 86,589 Various $ 18,184 $ 18,184 $ 18,184 $ 0

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 3 - RELATED PARTY TRANSACTIONS On June 27, 2011 the Company entered into a Multiple Advance Demand Note with The Shapiro Trust, owner of 40% of the outstanding equity in the Company. The Note is due upon Demand and bears an interest rate of 8% per annum. As of December 31, 2019 and December 31, 2018 the principal balance on the Note was $219,879 and $150,857, respectively. As of December 31, 2019 and December 31, 2018 the accrued interest on the Note was $31,960 and $16,046, respectively. The total principal and interest due The Shapiro Trust as of December 31, 2019 and December 31, 2018 was $251,839 and $166,903, respectively. See Note 4. On June 22, 2011 the Company entered into a Trademark License Agreement with Ann Shapiro, a beneficiary of the Shapiro Trust and wife of one of the Company's directors. Ms. Shapiro owns the Registered Trademark and cosmetic formulas. Under the terms of the Agreement the Company was granted an exclusive license to sell "Arrestage Mark and Formula" in exchange for a Royalty of $50,000 to be paid in three installments. Ms. Shapiro retains title and ownership of the Mark and Formulas. The Termination Date of the License is 2025. See Note 3.

Trademark License

Trademark License	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
TRADEMARK LICENSE	NOTE 4 - TRADEMARK LICENSE On June 22, 2011 the Company entered into a Trademark License Agreement with Ann Shapiro. Ms. Shapiro owns the Registered Trademark and cosmetic formulas. Under the terms of the Agreement the Company was granted an exclusive license to sell "Arrestage Mark and Formula" in exchange for a Royalty of $50,000 to be paid in three installments. Ms. Shapiro retains title and ownership of the Mark and Formulas. The Termination Date of the License is 2025. The Trademark License was originally recorded at a cost of $50,000 and tested for impairment in December 2014, at which time it was determined that the fair value of the License was zero and an impairment allowance of $50,000 was recorded. See Footnote 1-Intangible Assets. 2019 2018 Gross Carrying Amount Impairment Allowance Net Carrying Amount Gross Carrying Amount Impairment Allowance Net Carrying Amount Trademark License 50,000 (50,000 ) 0 50,000 (50,000 ) 0

Financing Activities

Financing Activities	12 Months Ended
	Dec. 31, 2019
Financing Activities [Abstract]
FINANCING ACTIVITIES	NOTE 5 - FINANCING ACTIVITIES Note Payable The Following is a summary of The Note Payable-Current December 31, 2019 December 31, 2018 Principal Interest payable Total Due Upon Demand Principal Interest payable Total Due Upon Demand Note Payable The following is a summary of the Royalty Fee Payable: Unsecured Demand Note Payable to The Shapiro Trust, due mupon demand. The Note Payable is a multiple advance demand Note with a stated interest rate of 8%. 219,879 31,960 251,839 150,857 16,046 166,903 Current Portion 219,879 31,960 251,839 150,857 16,046 166,903 Long Term portion - - - - - - Total 219,879 31,960 251,839 150,857 16,046 166,903 Royalty Fee Payable The following is a summary of the Royalty Fee Payable A Trademark Licenses Agreement was signed June 22, 2011 which calls for to Royalty Payments of $50,000 to be paid in three installments, with no interest, on or before the 15th day of the month for which the Royalty is due. 25,790 - 25,790 25,790 Current Portion 25,790 - 25,790 25,790 Long Term portion - - - - Total 25,790 - 25,790 25,790

Capital Stock and Stockholders'

Capital Stock and Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
CAPITAL STOCK and STOCKHOLDERS' EQUITY	NOTE 6 - CAPITAL STOCK and STOCKHOLDERS' EQUITY Description of Capital Stock--The Company has two classes of authorized capital stock: Common Stock and Preferred Stock. Both were authorized June 22, 2011 and both have a par value of $001. The holders of Common Stock are entitled to one vote per share. Rights and Preferences for the Preferred Stock will be determined by the Board of Directors prior to issuance of any Preferred Stock. There are 30,000,000 shares of Common Stock authorized. As of December 31, 2018, and 2017 there were 3,600,000 shares of Common Stock issued and outstanding. During the years ended December 31, 2019 and December 31, 20187, the Company did not issue any shares of common stock There are 5,000,000 shares of Preferred Stock authorized and zero outstanding as of December 31, 2019.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 - COMMITMENTS AND CONTINGENCIES There are no Commitments and Contingencies.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 - SUBSEQUENT EVENTS The Company has evaluated events subsequent to December 31, 2019 and the date the financial statements were available to be issued, to assess the need for potential recognition or disclosure. No subsequent events were noted that require recognition or disclosure in the financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Organization and Description of the Business	Organization and Description of the Business The Company was incorporated under the laws of the State of Nevada on June 15, 2011 and is in the Nutraceutical business and holds formulas on skin care products as well as brand formulas, and other intellectual property.
Use of Estimates by Management	Use of Estimates by Management The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents includes cash in banks and highly liquid investments with original maturities of three months or less that are readily convertible into cash and are not subject to significant risk from fluctuations in interest rates. As a result, the carrying amount of cash and cash equivalents approximates fair value.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company places its cash and cash equivalents with major financial institutions. At December 31, 2019 and December 31, 2018 the Company did not have any cash balances on deposit with banks which exceeded the balance insured by the FDIC, and does not believe that it is subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.
Intangible Assets	Intangible Assets Goodwill and Intangible Assets—Intangible assets with finite useful lives are amortized while intangible assets with indefinite useful lives are not amortized. Amortizable intangible assets are reviewed for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Indefinite-lived intangible assets are tested annually for impairment and when events or changes in circumstances indicate the carrying value may not be recoverable. The appropriateness of the indefinite-life classification of non-amortizable intangible assets is also reviewed as part of the annual testing or when circumstances warrant a change to a finite life. The Company performs its annual impairment testing as of December 31 each year, which is the last day of the Company's fiscal year. Intangible assets with indefinite useful lives (The Trademark License) are tested for impairment at the individual asset level by comparing the fair value of the indefinite-lived intangible asset to its carrying amount. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment charge is recognized to reduce the carrying amount to fair value. Fair values of indefinite-lived intangible assets are estimated using discounted cash flow ("DCF") models. In using a DCF method of establishing a fair value, management must make certain assumptions as to the likelihood of having cash flow from operations in the future based on past performance and prospects of sales in the future. The Company has no history of sales and no orders pending. Therefore, it is not possible to determine an appropriate level of cash receipts from operations into the future. Based on this assumption, during 2014 management determined that the fair value of the Trademark License under Generally Accepted Accounting Principles was zero. Accordingly, the Company has chosen to write the carrying value of the Trademark license to zero as of December 31, 2014.
Fair Value of Financial Instruments	Fair Value of Financial Instruments.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.
Ricks and Uncertainties	Ricks and Uncertainties The Company is subject to substantial business risks and uncertainties inherent in starting a new business. There is no assurance that the Company will be able to complete a business combination.
Basis of Presentation-Going Concern	Basis of Presentation-Going Concern The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern. However, as reflected in the accompanying financial statements, the Company has no operations, a net loss of ($84,790) for the year ended December 31, 2019, and ($117,695) for the year ended December 31, 2018, an accumulated deficit of ($431,331) as of December 31, 2019 and ($346,542) as of December 31, 2018, and a working capital deficiency of ($278,880) and ($194,090) at December 31, 2019 and December 31, 2018 respectively. This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company's ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. These financial statements are prepared on a going concern basis because the Directors, officers and significant shareholders have undertaken to provide continuing financial support so that the Company is able to pay its debts as and when they fall due. In addition, Management's plans to ensure the Company continues as a going concern include the pay-down of outstanding debt of the Company and funding of future operations using proceeds from the revenues expected to be generated from the sale of products and services within acquired companies. While the Company looks to acquire targeted acquisitions, adverse changes in market conditions or limits on the Company's ability to obtain financing could limit the Company's acquisition of such targets and the production, marketing and sale of products and services of the targeted acquisitions. The impact of such eventualities could influence future operations of the Company.
Income Taxes	Income Taxes The Company records deferred taxes in accordance with Statement of Financial Accounting Standards (SFAS) ASC 740, "Accounting for Income Taxes." The statement requires recognition of deferred tax assets and liabilities for temporary differences between the tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, the effect of net operating losses, based upon the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.
Earnings per Share	Earnings per Share Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding. There were no options or warrants outstanding at December 31, 2019 nor December 31, 2018. Diluted earnings per share is not shown for the periods in which the Company incurs a loss because it would be anti-dilutive.
Other	Other The Company has selected December 31 as its fiscal year end. The Company has paid no dividends. No advertising expense has been incurred. The Company consists of one reportable business segment. The Company has not entered into any leases.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of statutory tax rate to its effective tax rate	2019 2018 U.S. statutory rate 21 % 34 % Valuation allowance -21 % -34 % Effective tax rate 0 % 0 %
Schedule of deferred income tax assets	Year Ending Estimated NOL Carry-forward NOL Expires Estimated Tax Benefit from NOL Valuation Allowance Change in Valuation Allowance Net Tax Benefit December 31, 2019 $ 315,375 Various $ 66,229 $ 66,229 $ 13,826 $ 0 December 31, 2018 $ 249,537 Various $ 52,403 $ 52,403 $ 17,868 $ 0 December 31, 2017 $ 164,450 Various $ 34,535 $ 34,535 $ 7,414 $ 0 December 31, 2016 $ 129,147 Various $ 27,121 $ 27,121 $ 8,306 $ 0 December 31, 2015 $ 89,595 Various $ 18,815 $ 18,815 $ 631 $ 0 December 31, 2014 $ 86,589 Various $ 18,184 $ 18,184 $ 18,184 $ 0

Trademark License (Tables)

Trademark License (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	2019 2018 Gross Carrying Amount Impairment Allowance Net Carrying Amount Gross Carrying Amount Impairment Allowance Net Carrying Amount Trademark License 50,000 (50,000 ) 0 50,000 (50,000 ) 0

Financing Activities (Tables)

Financing Activities (Tables)	12 Months Ended
	Dec. 31, 2019
Financing Activities [Abstract]
Schedule of note payable and royalty fee payable	December 31, 2019 December 31, 2018 Principal Interest payable Total Due Upon Demand Principal Interest payable Total Due Upon Demand Note Payable The following is a summary of the Royalty Fee Payable: Unsecured Demand Note Payable to The Shapiro Trust, due mupon demand. The Note Payable is a multiple advance demand Note with a stated interest rate of 8%. 219,879 31,960 251,839 150,857 16,046 166,903 Current Portion 219,879 31,960 251,839 150,857 16,046 166,903 Long Term portion - - - - - - Total 219,879 31,960 251,839 150,857 16,046 166,903 Royalty Fee Payable The following is a summary of the Royalty Fee Payable A Trademark Licenses Agreement was signed June 22, 2011 which calls for to Royalty Payments of $50,000 to be paid in three installments, with no interest, on or before the 15th day of the month for which the Royalty is due. 25,790 - 25,790 25,790 Current Portion 25,790 - 25,790 25,790 Long Term portion - - - - Total 25,790 - 25,790 25,790

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2019USD ($)Segments / Number	Dec. 31, 2018USD ($)
Summary of Significant Accounting Policies (Textual)
Net loss	$ (84,790)	$ (117,695)
Accumulated deficit	(431,332)	(346,541)
Working capital deficiency	$ (278,880)	$ (194,090)
Number of reportable segment | Segments / Number	1

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
U.S. statutory rate	21.00%	34.00%
Valuation allowance	(21.00%)	(34.00%)
Effective tax rate	0.00%	0.00%

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Estimated NOL Carry-forward	$ 315,375	$ 249,537	$ 164,450	$ 129,147	$ 89,595	$ 86,589
NOL Expires	Various	Various	Various	Various	Various	Various
Estimated Tax Benefit from NOL	$ 66,229	$ 52,403	$ 34,535	$ 27,121	$ 18,815	$ 18,184
Valuation Allowance	66,229	52,403	34,535	27,121	18,815	18,184
Change in Valuation Allowance	13,826	17,868	7,414	8,306	631	18,184
Net Tax Benefit	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual)	12 Months Ended
	Dec. 31, 2019
Income Taxes (Textual)
Operating loss carryforwards expiry date, description	Expire in various years through 2037.

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended
	Jun. 27, 2011	Jun. 22, 2011	Dec. 31, 2019	Dec. 31, 2018
Related Party Transactions (Textual)
Outstanding equity percentage	40.00%
Interest rate	8.00%
Principal balance on the note			$ 219,879	$ 150,857
Accrued interest on the note			31,960	16,046
Total principal and interest			$ 251,839	$ 166,903
Royalty, description		The Company entered into a Trademark License Agreement with Ann Shapiro, a beneficiary of the Shapiro Trust and wife of one of the Company’s directors. Ms. Shapiro owns the Registered Trademark and cosmetic formulas. Under the terms of the Agreement the Company was granted an exclusive license to sell “Arrestage Mark and Formula” in exchange for a Royalty of $50,000 to be paid in three installments. Ms. Shapiro retains title and ownership of the Mark and Formulas.
Termination date, description		The Termination Date of the License is 2025.

Trademark License (Details)

Trademark License (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Gross Carrying Amount	$ 50,000	$ 50,000
Impairment Allowance	(50,000)	(50,000)
Net Carrying Amount	$ 0	$ 0

Financing Activities (Details)

Financing Activities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Note payable, principal	$ 219,879	$ 150,857
Note payable, interest payable	31,960	16,046
Note payable, total due upon demand	251,839	166,903
Royalty fee payable, Principal	25,790	25,790
Royalty fee payable, Interest payable
Royalty fee payable, total due upon demand	25,790
Royalty Fee payable [Member] | A Trademark Licenses Agreement [Member]
Royalty fee payable, Principal	25,790	25,790
Royalty fee payable, Interest payable
Royalty fee payable, total due upon demand	25,790
Current Portion [Member] | Royalty Fee payable [Member]
Royalty fee payable, Principal	25,790	25,790
Royalty fee payable, Interest payable
Royalty fee payable, total due upon demand	25,790
Long Term Portion [Member] | Royalty Fee payable [Member]
Royalty fee payable, Principal
Royalty fee payable, Interest payable
Royalty fee payable, total due upon demand
Note Payable [Member] | Current Portion [Member]
Note payable, principal	219,879	150,857
Note payable, interest payable	31,960	16,046
Note payable, total due upon demand	251,839	166,903
Note Payable [Member] | Long Term Portion [Member]
Note payable, principal
Note payable, interest payable
Note payable, total due upon demand
Note Payable [Member] | Unsecured Demand [Member]
Note payable, principal	219,879	150,857
Note payable, interest payable	31,960	16,046
Note payable, total due upon demand	$ 251,839	$ 166,903

Financing Activities (Details T

Financing Activities (Details Textual) - Note Payable [Member]	12 Months Ended
	Dec. 31, 2019
Financing Activities (Textual)
Stated interest rate	8.00%
Royalty fee payable, description	A Trademark Licenses Agreement was signed June 22, 2011 which calls for to Royalty Payments of $50,000 to be paid in three installments, with no interest, on or before the 15th day of the month for which the Royalty is due.

Trademark License (Details Text

Trademark License (Details Textual) - USD ($)	1 Months Ended
	Jun. 22, 2011	Dec. 31, 2019	Dec. 31, 2018
Trademark License (Textual)
Royalty, description	The Company entered into a Trademark License Agreement with Ann Shapiro. Ms. Shapiro owns the Registered Trademark and cosmetic formulas. Under the terms of the Agreement the Company was granted an exclusive license to sell “Arrestage Mark and Formula” in exchange for a Royalty of $50,000 to be paid in three installments. Ms. Shapiro retains title and ownership of the Mark and Formulas.
Termination date, description	The Termination Date of the License is 2025.
Trademark license		$ 50,000	$ 50,000
Impairment allowance		$ 50,000

Capital Stock and Stockholder_2

Capital Stock and Stockholders' Equity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Capital Stock and Stockholders' Equity (Textual)
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	3,600,000	3,600,000
Common stock, shares outstanding	3,600,000	3,600,000
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding
Common stock, voting rights, description	The holders of Common Stock are entitled to one vote per share.